Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation.
OBJECTIVE
Using the fluconazole-zidovudine (AZT) interaction as a model, to determine whether inhibition of UDP-glucuronosyltransferase (UGT) catalysed drug metabolism in vivo could be predicted quantitatively from in vitro kinetic data generated in the presence and absence bovine serum albumin (BSA).


METHODS
Kinetic constants for AZT glucuronidation were generated using human liver microsomes (HLM) and recombinant UGT2B7, the principal enzyme responsible for AZT glucuronidation, as the enzyme sources with and without fluconazole. K(i) values were used to estimate the decrease in AZT clearance in vivo.


RESULTS
Addition of BSA (2%) to incubations decreased the K(m) values for AZT glucuronidation by 85-90% for the HLM (923 +/- 357 to 91 +/- 9 microm) and UGT2B7 (478-70 microm) catalysed reactions, with little effect on V(max). Fluconazole, which was shown to be a selective inhibitor of UGT2B7, competitively inhibited AZT glucuronidation by HLM and UGT2B7. Like the K(m), BSA caused an 87% reduction in the K(i) for fluconazole inhibition of AZT glucuronidation by HLM (1133 +/- 403 to 145 +/- 36 microm) and UGT2B7 (529 to 73 microm). K(i) values determined for fluconazole using HLM and UGT2B7 in the presence (but not absence) of BSA predicted an interaction in vivo. The predicted magnitude of the interaction ranged from 41% to 217% of the reported AUC increase in patients, depending on the value of the in vivo fluconazole concentration employed in calculations.


CONCLUSIONS
K(i) values determined under certain experimental conditions may quantitatively predict inhibition of UGT catalysed drug glucuronidation in vivo.
Department of Clinical Pharmacology, Flinders University and Flinders Medical Centre, Adelaide, SA, Australia.
Verawan
V
Uchaipichat
Leanne K
LK
Winner
Peter I
PI
Mackenzie
David J
DJ
Elliot
J Andrew
JA
Williams
John O
JO
Miners
D000408:Alamethicin / Q000494:pharmacology; D000935:Antifungal Agents / Q000494:pharmacology*; D000963:Antimetabolites / Q000378:metabolism*; D002460:Cell Line; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D015725:Fluconazole / Q000494:pharmacology*; D014453:Glucuronosyltransferase / Q000037:antagonists & inhibitors; D006801:Humans; D008862:Microsomes, Liver / Q000378:metabolism; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors; D012710:Serum Albumin, Bovine / Q000494:pharmacology; D014268:Trifluoperazine / Q000032:analysis; D014475:Uncoupling Agents / Q000494:pharmacology; D015215:Zidovudine / Q000378:metabolism*
D000935:Antifungal Agents; D000963:Antimetabolites; D011994:Recombinant Proteins; D014475:Uncoupling Agents; D014268:Trifluoperazine; D000408:Alamethicin; D012710:Serum Albumin, Bovine; D015215:Zidovudine; D015725:Fluconazole; C491474:UGT2B7 protein, human; D014453:Glucuronosyltransferase